Codes J9275 to J9601
Page 6 of 6 of the hub's 847 codes, in code order: 70 codes on this page have an indexed reference page and are in the table, and the other 1 are listed as text below it.
| Code | Descriptor | Unit | Limit | MUE | Col-2 pairs | Articles |
|---|---|---|---|---|---|---|
| J9275 | Injection, cosibelimab-ipdl, 2 mg | 2 MG | $21.989 | 600 | — | — |
| J9276 | Injection, zanidatamab-hrii, 2 mg | 2 MG | $25.734 | 1500 | — | — |
| J9277 | Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph | 1 MG | $32.307 | — | — | — |
| J9278 | Injection, carboplatin (avyxa), 1 mg | 1 MG | $5.226 | — | — | — |
| J9280 | Injection, mitomycin, 5 mg | 5 MG | $34.838 | 12 | — | — |
| J9281 | Mitomycin pyelocalyceal instillation, 1 mg | 1 MG | $329.071 | 80 | — | — |
| J9282 | Mitomycin, intravesical instillation, 1 mg | 1 MG | $272.918 | 80 | — | — |
| J9286 | Injection, glofitamab-gxbm, 2.5 mg | 2.5 MG | $2,859.117 | 12 | — | — |
| J9289 | Injection, nivolumab, 2 mg and hyaluronidase-nvhy | 2 MG | $27.989 | 600 | — | — |
| J9292 | Injection, pemetrexed dipotassium, 10 mg | 10 MG | $76.69 | 150 | — | — |
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg | 5 MG | $19.418 | 8 | — | — |
| J9294 | Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg | 10 MG | $3.678 | 150 | — | — |
| J9295 | Injection, necitumumab, 1 mg | 1 mg | $5.731 OPPS | 800 | — | — |
| J9297 | Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg | 10 MG | $4.879 | 150 | — | — |
| J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | 3 mg/1 mg | $205.442 | 160 | — | — |
| J9299 | Injection, nivolumab, 1 mg | 1 MG | $34.191 | 480 | — | — |
| J9301 | Injection, obinutuzumab, 10 mg | 10 MG | $85.039 | 100 | — | — |
| J9303 | Injection, panitumumab, 10 mg | 10 MG | $183.275 | 90 | — | — |
| J9304 | Injection, pemetrexed (pemfexy), 10 mg | 10 MG | $92.505 | 150 | — | — |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 10 MG | $1.23 | 150 | — | — |
| J9306 | Injection, pertuzumab, 1 mg | 1 MG | $17.269 | 840 | — | — |
| J9307 | Injection, pralatrexate, 1 mg | 1 MG | $384.572 | 80 | — | — |
| J9308 | Injection, ramucirumab, 5 mg | 5 MG | $76.398 | 280 | — | — |
| J9309 | Injection, polatuzumab vedotin-piiq, 1 mg | 1 MG | $144.103 | 280 | — | — |
| J9311 | Injection, rituximab 10 mg and hyaluronidase | 10 mg | $36.265 | 160 | — | yes |
| J9312 | Injection, rituximab, 10 mg | 10 MG | $72.094 | 150 | — | yes |
| J9314 | Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg | 10 MG | $10.986 | 150 | — | — |
| J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | 10 MG | $59.491 | 180 | — | — |
| J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg | 2.5 MG | $37.536 | 648 | — | — |
| J9318 | Injection, romidepsin, non-lyophilized, 0.1 mg | 0.1 MG | $32.864 | 475 | — | — |
| J9319 | Injection, romidepsin, lyophilized, 0.1 mg | 0.1 MG | $32.343 | 500 | — | — |
| J9321 | Injection, epcoritamab-bysp, 0.16 mg | 0.16 MG | $57.975 | 300 | — | — |
| J9322 | Injection, pemetrexed (bluepoint), not therapeutically equivalent to j9305, 10 mg | 10 mg | $10.60 OPPS | 150 | — | — |
| J9324 | Injection, pemetrexed (pemrydi rtu), 10 mg | 10 MG | $63.58 | 150 | — | — |
| J9325 | Injection, talimogene laherparepvec, per 1 million plaque forming units | 1 millionPFU | $77.657 | 400 | — | — |
| J9326 | Injection, telisotuzumab vedotin-tllv, 1 mg | 1 MG | $145.946 | 200 | — | — |
| J9328 | Injection, temozolomide, 1 mg | 1 MG | $10.41 | 400 | — | — |
| J9329 | Injection, tislelizumab-jsgr, 1mg | 1 MG | $58.086 | 400 | — | — |
| J9330 | Injection, temsirolimus, 1 mg | 1 MG | $27.707 | 50 | — | — |
| J9331 | Injection, sirolimus protein-bound particles, 1 mg | 1 MG | $91.03 | 300 | — | — |
| J9332 | Injection, efgartigimod alfa-fcab, 2mg | 2 MG | $32.347 | 600 | — | — |
| J9333 | Injection, rozanolixizumab-noli, 1 mg | 1 MG | $23.626 | 840 | — | — |
| J9334 | Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc | 2 MG | $33.59 | 504 | — | — |
| J9341 | Injection, thiotepa (tepylute), 1 mg | 1 MG | $37.841 | 60 | — | — |
| J9342 | Injection, thiotepa, not otherwise specified, 1 mg | 1 MG | $5.871 | 60 | — | — |
| J9345 | Injection, retifanlimab-dlwr, 1 mg | 1 MG | $30.932 | 500 | — | — |
| J9347 | Injection, tremelimumab-actl, 1 mg | 1 MG | $146.991 | 300 | — | — |
| J9348 | Injection, naxitamab-gqgk, 1 mg | 1 MG | $685.988 | 160 | — | — |
| J9349 | Injection, tafasitamab-cxix, 2 mg | 2 MG | $14.428 | 900 | — | — |
| J9350 | Injection, mosunetuzumab-axgb, 1 mg | 1 MG | $676.484 | 60 | — | — |
| J9351 | Injection, topotecan, 0.1 mg | 0.1 MG | $2.067 | 120 | — | — |
| J9353 | Injection, margetuximab-cmkb, 5 mg | 5 MG | $56.046 | 450 | — | — |
| J9354 | Injection, ado-trastuzumab emtansine, 1 mg | 1 MG | $43.86 | 600 | — | — |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 10 MG | $68.871 | 120 | — | — |
| J9356 | Injection, trastuzumab, 10 mg and hyaluronidase-oysk | 10 MG | $58.038 | 60 | — | — |
| J9357 | Injection, valrubicin, intravesical, 200 mg | 200 MG | $1,230.664 | 4 | — | — |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | 1 MG | $32.653 | 1000 | — | — |
| J9359 | Injection, loncastuximab tesirine-lpyl, 0.075 mg | 0.075 MG | $226.565 | 400 | — | — |
| J9360 | Injection, vinblastine sulfate, 1 mg | 1 MG | $5.754 | 40 | — | — |
| J9361 | Injection, efbemalenograstim alfa-vuxw, 0.5 mg | 0.5 MG | $121.429 | 40 | — | — |
| J9362 | Injection, trabectedin, 0.01 mg | 0.01 MG | $41.844 | — | — | — |
| J9370 | Vincristine sulfate, 1 mg | 1 MG | $9.426 | 4 | — | — |
| J9380 | Injection, teclistamab-cqyv, 0.5 mg | 0.5 MG | $35.818 | 918 | — | — |
| J9381 | Injection, teplizumab-mzwv, 5 mcg | 5 MCG | $39.274 | 800 | — | — |
| J9382 | Injection, zenocutuzumab-zbco, 1 mg | 1 MG | $33.869 | 750 | — | — |
| J9390 | Injection, vinorelbine tartrate, 10 mg | 10 MG | $4.148 | 36 | — | — |
| J9393 | Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg | 25 mg | $41.67 OPPS | 20 | — | — |
| J9395 | Injection, fulvestrant, 25 mg | 25 MG | $5.021 | 20 | — | — |
| J9400 | Injection, ziv-aflibercept, 1 mg | 1 MG | $9.702 | 500 | — | — |
| J9601 | Injection, linvoseltamab-gcpt, 1 mg | 1 MG | $99.134 | — | — | — |
Show the other 1 codes on this page (pages not yet in search results)
- J9376 Injection, pozelimab-bbfg, 1 mg · OPPS $91.73
How to read this page
The limit is the Medicare Part B payment allowance per billing unit for the October 2026 quarter, not per dose: divide the quantity administered by the unit in the descriptor to get the units billed, then multiply. Codes marked OPPS have no ASP limit and show the hospital outpatient rate per unit instead, and codes without a limit are priced by the contractor or carry a limit of zero in the CMS file. The MUE column is the practitioner Medically Unlikely Edit, the most units CMS expects on one date of service; the facility and supplier limits can differ and are on each code page. Column-2 pairs counts the active NCCI procedure-to-procedure edits in which the code is the bundled component, and Articles marks codes that a Medicare Administrative Contractor lists in a current billing and coding article.
Codes are listed in code order across 6 pages, and every code of the hub appears on exactly one of them. A code shown as text still has its own reference page with the same data; that page is kept out of search results because fewer CMS files join to the code, few people search for it, or its text is too close to another code's page, and the hub links the pages that are meant to be found. Amounts are Medicare national figures before locality and state adjustment.
Finding a code faster
Look up any code by number with the code search, or go back to the Drugs administered other than oral method, chemotherapy drugs (J codes) hub for its most searched codes and the answers to common questions. The MUE lookup shows every unit limit for a code, the NCCI edit checker tests whether two codes are bundled, and the HCPCS code lookup lists every range, drug and drug-class hub. For a drug you know by name, the J code index by drug name lists every code a generic or brand name bills under, and the ASP pricing file guide explains how the quarterly limits are set.
For teams evaluating QuickIntell software
Evaluate software for HCPCS coding workflows
Evaluating a recurring coding workflow? Review QuickCode for qualified coder review, documentation clarification and the billing handoff. Use your unit, modifier and edit questions to confirm the supported scope; a published CMS table does not establish an automated claim check.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
Disclaimer
Operational reference compiled from CMS publications. Amounts are Medicare national figures before locality and state adjustment; other payers differ. CPT codes appear as numbers only. This continuation page is kept out of search results; the hub and each code's own page are the pages meant to be found. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.